【佳學(xué)基因檢測(cè)】野生型p53和雙重自殺基因在兔肝癌介入治療中的作用

如何知道小孩是否有基因突變的方法

探索腫瘤的基因組學(xué)特征與治療方案設(shè)計(jì)體會(huì)到《Acta Cir Bras》在. 2012 Aug;27(8):522-8.發(fā)表了一篇題目為《野生型p53和雙重自殺基因在肝癌介入治療中的作用》腫瘤靶向藥物治療基因檢測(cè)臨床研究文章。該研究由Hong-xin Niu , Tong Du, Zhong-fa Xu, Xi-kun Zhang, Ruo-gu Wang等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測(cè)與分析的重要性。

腫瘤靶向藥物測(cè)序基因檢測(cè)研究?jī)?nèi)容關(guān)鍵詞：

碘油栓塞, p53 基因治療,TK,CD,抑制腫瘤,肝癌

腫瘤靶向治療基因檢測(cè)臨床應(yīng)用結(jié)果

目的：探討介入性碘油栓塞和多基因治療聯(lián)合局部化療治療兔VX2型肝癌的可行性。方法：45只腫瘤直徑大于2cm的家兔隨機(jī)分為5組（n=9每組）。在第 1 組中，動(dòng)物用 0.9% 氯化鈉處理。在第 2 組中，動(dòng)物接受碘油栓塞。在第 3 組中，動(dòng)物接受了碘油栓塞和 p53 基因治療。在第 4 組中，動(dòng)物接受碘油栓塞和 TK/CD 基因治療。在第 5 組中，動(dòng)物接受碘油栓塞和 p53 和 TK/CD 基因治療。介入治療前及介入治療后10天進(jìn)行超聲及CT檢查。結(jié)果：成功建立兔肝癌VX2模型，介入治療順利進(jìn)行。介入治療10天后，5組間腫瘤體積有顯著差異（p<0.05），不同治療可抑制腫瘤生長(zhǎng)。對(duì)癌癥生長(zhǎng)的抑制在第 5 組中賊為明顯。析因分析顯示，使用 p53 或 TK/CD 和碘油栓塞的基因治療獨(dú)立地對(duì)癌癥生長(zhǎng)產(chǎn)生顯著抑制作用。此外，第5組對(duì)腫瘤生長(zhǎng)速度的抑制賊為明顯。結(jié)論：基因治療聯(lián)合碘油栓塞可有效抑制腫瘤生長(zhǎng)，延長(zhǎng)生存時(shí)間。這些發(fā)現(xiàn)證明了多基因療法聯(lián)合碘油栓塞治療肝癌的有效性。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國(guó)際數(shù)據(jù)庫(kù)描述：

Purpose: To investigate the feasibility of interventional lipiodol embolism and multigene therapy in combination with focal chemotherapy in the treatment of VX2 liver cancer in rabbits.Methods: Forty five rabbits with cancer larger than 2cm in diameter were randomly divided into five groups (n=9 per group). In Group 1, animals were treated with 0.9% sodium chloride. In Group 2, animals received lipiodol embolism. In Group 3, animals received lipiodol embolism and p53 gene therapy. In Group 4, animals received lipiodol embolism and TK/CD gene therapy. In Group 5, animals received lipiodol embolism and p53 and TK/CD gene therapy. Ultrasonography and CT were performed before and at ten days after interventional therapy.Results: The VX2 model of liver cancer was successfully established in rabbits and interventional therapy smoothly performed. At ten days after interventional therapy, significant difference in the tumor volume was noted among five groups (p<0.05) and different treatments could inhibit the cancer growth. The inhibition of cancer growth was the most evident in the Group 5. Factorial analysis revealed gene therapy with p53 or TK/CD and lipiodol embolism independently exert significantly inhibitory effect on cancer growth. In addition, the suppression on tumor growth rate was the most obvious in the Group 5.Conclusions: Combination of gene therapy with lipiodol embolism can effectively inhibit the cancer growth and prolong the survival time. These findings demonstrate the effectiveness of multigene therapy in combination with lipiodol embolism in the treatment of liver cancer.